Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //
Today's Change
Volume
Real-Time Last Update TSX Last Sale

Today's Trading

Day Low 0.0400
Day High 0.0450
Open:0.0400
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Acerus Pharmaceuticals Corp is a specialty pharmaceutical company. Principally, it is engaged in the development, manufacture, marketing, and distribution of branded products in men's and women's health. The company markets its product under brand ESTRACE, NATESTO, GYNOFLOR and TEFINA. The ESTRACE brand markets in Canada and is for the symptomatic relief of menopausal symptoms. Its NATESTO is a licensed nasal gel technology for replacement therapy in adult males diagnosed with hypogonadism. GYNOFLOR offers ultra-low dose vaginal estrogen therapy. Its TEFINA brand product is a low-dose nasal testosterone gel treatment in development for female sexual dysfunction.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

No rating

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Acerus Appoints Dr. Geoff Cotton to Its Board of Directors
- BusinessWire - Mon May 4, 6:30AM CDT
BusinessWire - CMTX
Mon May 4, 6:30AM CDT
Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the appointment of Dr. Geoff Cotton, MB BS, MBA to its Board of Directors.
New Data Demonstrates That NATESTO® Increases Serum Testosterone And Improves Symptoms While Maintaining Normal Semen Parameters In Men With Low Testosterone Through Six Months
- PR Newswire - Thu Oct 17, 7:30AM CDT
PR Newswire - PRNW
Thu Oct 17, 7:30AM CDT
TORONTO , Oct. 17, 2019 /PRNewswire/ -- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced the presentation of data from the NATESTO ® Spermatogenesis Study as part of the "Late Breaking" Abstract Session at the 75th Annual American Society for Reproductive Medicine (ASRM) Scientific Conference in Philadelphia, PA. Yesterday's presentation was one of only six abstracts accepted as part of this session.
Acerus And Aytu Bioscience To Co-Promote NATESTO® In The United States
PR Newswire - Tue Jul 30, 6:00AM CDT
PR Newswire - PRNW
Tue Jul 30, 6:00AM CDT
TORONTO , July 30, 2019 /PRNewswire/ -- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) today announced that it will be taking an expanded role in the commercialization of NATESTO ® in the U.S. The company has entered into an amended and restated licensing agreement with Aytu BioScience, Inc. (NASDAQ: AYTU), which will, upon closing, move the partnership from an out-license model to a co-promotion arrangement that the companies believe will leverage their collective product, marketplace and Men's Health experience to capture a significant share of the U.S. market for NATESTO ® .
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 0.0300 +33.33% increase
on 12/30/20
Period Open:0.0350
Price movement based on the high, low and last over the given period.
0.0450 -11.11% decrease
on 01/15/21
+0.0050 (+14.29%) increase
since 12/15/20
3-Month 0.0250 +60.00% increase
on 11/24/20
Period Open:0.0450
Price movement based on the high, low and last over the given period.
0.0450 -11.11% decrease
on 01/15/21
-0.0050 (-11.11%) decrease
since 10/15/20
52-Week 0.0250 +60.00% increase
on 11/24/20
Period Open:0.0800
Price movement based on the high, low and last over the given period.
0.1300 -69.23% decrease
on 02/18/20
-0.0400 (-50.00%) decrease
since 01/15/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies